Tadalafil + Placebo

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Erectile Dysfunction

Conditions

Erectile Dysfunction, Benign Prostatic Hyperplasia

Trial Timeline

Mar 1, 2009 → Jul 1, 2010

NCT ID

NCT00855582

About Tadalafil + Placebo

Tadalafil + Placebo is a phase 3 stage product being developed by Eli Lilly for Erectile Dysfunction. The current trial status is completed. This product is registered under clinical trial identifier NCT00855582. Target conditions include Erectile Dysfunction, Benign Prostatic Hyperplasia.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (14)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01865084	Phase 3	Terminated	Sep 1, 2013	Mar 1, 2016	Muscular Dystrophy, Duchenne
NCT01460342	Phase 3	Completed	Dec 1, 2011	Oct 1, 2012	Benign Prostatic Hyperplasia
NCT01152190	Phase 3	Completed	Sep 1, 2010	Jul 1, 2012	Benign Prostatic Hyperplasia
NCT01130532	Approved	Completed	Aug 1, 2010	Jan 1, 2012	Erectile Dysfunction
NCT01026818	Approved	Completed	Nov 1, 2009	Oct 1, 2012	Erectile Dysfunction
NCT00848081	Phase 3	Completed	Mar 1, 2009	Dec 1, 2009	Benign Prostatic Hyperplasia
NCT00855582	Phase 3	Completed	Mar 1, 2009	Jul 1, 2010	Erectile Dysfunction
NCT00836693	Phase 3	Completed	Jan 1, 2009	Jan 1, 2010	Erectile Dysfunction
NCT00422734	Phase 3	Completed	Nov 1, 2006	Jan 1, 2008	Impotence
NCT00538564	Phase 2	Withdrawn	Nov 1, 2006	Aug 1, 2009	Sickle Cell Anemia
NCT00386009	Phase 2	Completed	Oct 1, 2006	May 1, 2008	Benign Prostatic Hyperplasia
NCT00547625	Phase 2	Completed	Oct 1, 2004	Jul 1, 2005	Prostatic Hyperplasia
NCT00382135	Approved	Completed	Nov 1, 2003	Dec 1, 2005	Erectile Dysfunction
NCT00381732	Phase 3	Completed	Oct 1, 2003	Jun 1, 2006	Erectile Dysfunction

Competing Products

20 competing products in Erectile Dysfunction

See all competitors

Product	Company	Stage	Hype Score
tadalafil + placebo	Eli Lilly	Phase 3	77
YHD1023 + YHD1023 + YHD1023 + Cialis + Placebo	Yuhan	Phase 2	52
Tacrolimus + Placebo	Astellas Pharma	Approved	85
Mirabegron	Astellas Pharma	Phase 1/2	41
LY2452473 + Tadalafil + LY900010	Eli Lilly	Phase 1	33
tadalafil + placebo	Eli Lilly	Phase 3	77
tadalafil	Eli Lilly	Phase 3	77
LY2452473 + tadalafil + placebo (tadalafil) + placebo (LY2452473)	Eli Lilly	Phase 2	52
Tadalafil	Eli Lilly	Approved	85
tadalafil + placebo	Eli Lilly	Approved	85
Tadalafil + Sildenafil Citrate	Eli Lilly	Approved	85
Placebo + Tadalafil	Eli Lilly	Approved	85
Tadalafil + Placebo	Eli Lilly	Approved	85
tadalafil	Eli Lilly	Approved	85
Tadalafil + Sildenafil	Eli Lilly	Approved	85
tadalafil once a day [T(OaD)] + sildenafil citrate as needed [S(PRN)] + tadalafil as needed [T(PRN)]	Eli Lilly	Phase 3	77
Tadalafil + Placebo	Eli Lilly	Approved	85
Dapoxetine	Johnson & Johnson	Phase 3	77
dapoxetine	Johnson & Johnson	Phase 3	77
Placebo + Dapoxetine + PDE5I (phosphodiesterase-5 inhibitor)	Johnson & Johnson	Phase 3	77

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved

Olanzapine + PlaceboApproved

exenatide and sitagliptin + exenatide and placeboApproved

Tirzepatide + PlaceboApproved

tadalafilApproved